Abstract
Voltage-gated sodium channels have been shown to play a critical role in neuropathic pain. A series of low molecular weight biaryl substituted pyrazole carboxamides were identified with good in-vitro potency and in-vivo efficacy. Compound 26, a Nav1.7 blocker has excellent efficacy in the Chung model of neuropathic pain.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Dogs
-
Haplorhini
-
Humans
-
Microsomes, Liver / metabolism
-
NAV1.7 Voltage-Gated Sodium Channel
-
Neuralgia / drug therapy*
-
Pyrazoles / chemistry*
-
Pyrazoles / pharmacokinetics
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use*
-
Rats
-
Sodium Channel Blockers / chemistry*
-
Sodium Channel Blockers / pharmacokinetics
-
Sodium Channel Blockers / pharmacology
-
Sodium Channel Blockers / therapeutic use*
-
Sodium Channels / metabolism*
-
Structure-Activity Relationship
Substances
-
NAV1.7 Voltage-Gated Sodium Channel
-
Pyrazoles
-
SCN9A protein, human
-
Sodium Channel Blockers
-
Sodium Channels